| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| GLP1R | HOT GLR-H5253 | Human GLP1R Protein, Fc Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $395.00 100ug | ||
| GLP1R | HOTAvitag GLR-H82E3 | Biotinylated Human GLP1R Protein, His,Avitag™ (HPLC verified) | Human | HEK293 | ![]() | HPLCSDS-PAGE | $415.00 25ug | ||
| GLP1R | Human GLP1R Full Length Protein (L260F), Flag,His Tag (Detergent) | Human | HEK293 | ![]() | $805.00 20ug | ||||
| GLP1R | Human GLP1R Protein, His Tag, low Endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $500.00 100ug | |||
| GLP1R | Human GLP1R Full Length Protein (VLP) | Human | HEK293 | $620.00 20ug | |||||
| GLP1R | Avitag GLR-H82D3 | Biotinylated Human GLP1R Full Length Protein, Flag Tag&His,Avitag™ (Detergent) | Human | HEK293 | ![]() | $805.00 20ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BioGlutide | NA-931 | Phase 3 Clinical | Biomed Industries Inc | Body Weight; Body Weight Changes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Obesity; Overweight; Weight Loss | Details |
| Bionetide | NA-921 | Phase 3 Clinical | Biomed Industries Inc | Fragile X Syndrome; Rett Syndrome | Details |
| ZT-006 | ZT-006; ZT006 | Phase 2 Clinical | Beijing QL Biopharmaceutical Co Ltd | Alzheimer Disease; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| HM-15275 | HM15275; HM-15275 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Obesity | Details |
| SYH-2082 | SYH-2082; SYH2082 | Phase 1 Clinical | Beijing Kangchuanglian Biopharmaceutical Technology Research Co Ltd | Obesity; Overweight | Details |
| SNA-003 | SNA003; SNA-003 | Phase 1 Clinical | SN BioScience | Diabetes Mellitus; Obesity | Details |
| CA-111 | CA-111; CA111 | Phase 1 Clinical | Chongqing Chenan Biopharmaceutical Co Ltd | Body Weight | Details |
| ACT-300 | ACT300; ACT-300 | Phase 1 Clinical | Xiamen Amoytop Biotech Co Ltd | Digestive System Diseases; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| KAI-4729 | HRS-4729; KAI-4729 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| ZT-003 | ZT003; ZT-003 | Phase 1 Clinical | Beijing QL Biopharmaceutical Co Ltd | Diabetes Mellitus; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
| ANY-002 | ANY-002; ANY002 | Phase 1 Clinical | Anya Biopharm Inc | Details | |
| KN-069 | KN069; KN-069 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Metabolic Diseases; Obesity; Overweight | Details |
| semaglutide (Lexaria Bioscience) | Clinical | Lexaria Bioscience Corp | Diabetes Mellitus | Details |